Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2007-08-28
2007-08-28
Kemmerer, Elizabeth C. (Department: 1646)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S141100, C530S388230, C530S388240, C530S388100
Reexamination Certificate
active
10688925
ABSTRACT:
The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), in particular human antibodies, and antibody fragments, including those that inhibit GDF-8 activity in vitro and/or in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle or bone, or disorders of insulin metabolism.
REFERENCES:
patent: 5639638 (1997-06-01), Wozney et al.
patent: 5700911 (1997-12-01), Wozney et al.
patent: 5723125 (1998-03-01), Chang et al.
patent: 5756457 (1998-05-01), Wang et al.
patent: 5827733 (1998-10-01), Lee et al.
patent: 5914234 (1999-06-01), Lee et al.
patent: 5994618 (1999-11-01), Lee et al.
patent: 6004937 (1999-12-01), Wood et al.
patent: 6096506 (2000-08-01), Lee et al.
patent: 6340668 (2002-01-01), Celeste et al.
patent: 6368597 (2002-04-01), Strassmann et al.
patent: 6369201 (2002-04-01), Barker et al.
patent: 6437111 (2002-08-01), Wozney et al.
patent: 6656475 (2003-12-01), Lee et al.
patent: 6696260 (2004-02-01), Lee et al.
patent: 6835544 (2004-12-01), Mathews et al.
patent: 2002/0150577 (2002-10-01), Lee et al.
patent: 2003/0104406 (2003-06-01), Wolfman et al.
patent: 2003/0138422 (2003-07-01), Aghajanian et al.
patent: 2003/0162714 (2003-08-01), Hill et al.
patent: 2003/0180306 (2003-09-01), Hill et al.
patent: 2004/0077053 (2004-04-01), Lee et al.
patent: 2004/0138118 (2004-07-01), Wolfman et al.
patent: 2004/0181033 (2004-09-01), Han et al.
patent: 2004/0223966 (2004-11-01), Wolfman et al.
patent: 2005/0043232 (2005-02-01), Lee et al.
patent: 1 061 940 (2003-12-01), None
patent: 1 444 985 (2004-08-01), None
patent: WO94/21681 (1994-09-01), None
patent: WO94-26892 (1994-11-01), None
patent: WO96-01845 (1996-01-01), None
patent: WO99-24058 (1999-05-01), None
patent: WO99-45949 (1999-09-01), None
patent: WO99/56768 (1999-11-01), None
patent: WO 00-11163 (2000-03-01), None
patent: WO 00/43781 (2000-07-01), None
patent: WO 01-64888 (2001-09-01), None
patent: WO 02-09641 (2002-02-01), None
patent: WO 02-068650 (2002-09-01), None
patent: WO 03/027248 (2003-04-01), None
patent: WO 03/037248 (2003-05-01), None
Wells, 1990, Biochemistry 29:8509-8517.
Ngo et al., 1994, The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495.
Bork, 2000, Genome Research 10:398-400.
Skolnick et al., 2000, Trends in Biotech. 18(1):34-39.
Doerks et al., 1998, Trends in Genetics 14:248-250.
Smith et al., 1997, Nature Biotechnology 15:1222-1223.
Brenner, 1999, Trends in Genetics 15:132-133.
Bork et al., 1996, Trends in Genetics 12:425-427.
Alexander et al., “Human Parathyroid Hormone 1-34 Reverses Bone Loss In Ovariectomized Mice”,J. Bone Min. Res. 16:1665-1673 (2001).
Andersson et al., “Repeated In Vivo Determinations of Bone Mineral Density During Parathyroid Hormone Treatment in Ovariectomized Mice”,J. Endocrinol. 170:529-537 (2001).
Ashmore et al., “Comparative Aspects of Muscle Fiber Types in Fetuses of the Normal and ‘Double-Muscled’ Cattle”,Growth38:501-506 (1974).
Bogdanovich et al., “Functional Improvement of Dystrophic Muscle by Myostatin Blockade”,Nature420:418-421 (2002).
Brown et al., “Physicochemical Activation of Recombinant Latent Transforming Growth Factor-beta's 1,2, and 3”,Growth Factors3:35-43 (1990).
Derynck et al., “Human Transforming Growth Factor-β Complementary DNA Sequence and Expression in Normal and Transformed Cells”,Nature316:701-705 (1985).
Gamer et al., “A Novel BMP Expressed in Developing Mouse Limb, Spinal Cord, and Tail Bud Is a Potent Mesoderm Inducer inXenopusEmbryos”,Dev. Biol. 208:222-232 (1999).
Gentry et al., “The Pro Domain of Pre-Pro-Transforming Growth Factor β1 When Independently Expressed Is a Functional Binding Protein for the Mature Growth Factor”,Biochemistry29:6851-6857 (1990).
Gonzalez-Cadavid et al., “Organization of the Human Myostatin Gene and Expression in Healthy Men and HIV-Infected Men With Muscle Wasting”,PNAS95:14938-14943 (1998).
Hamrick et al., “Femoral Morphology and Cross-Sectional Geometry of Adult Myostatin-Deficient Mice”,Bone27:343-349 (2000).
Hill et al., “The Myostatin Propeptide and the Follistatin-Related Gene Are Inhibitory Binding Proteins of Myostatin in Normal Serum”,J. Biol. Chem. 277:40735-40741 (2002).
Hoodless et al., “Mechanisms and Function of Signaling by the TGFβ Superfamily”,Current Topics in Microbiology and Immunologypp. 236-272 (1998).
Kambadur et al., “Mutations inMyostatin(GDF8) In Double-Muscled Belgian Blue and Piedmontese Cattle”,Genome Res. 7:910-915 (1997).
Kim et al., “Inhibition of Preadipocyte Differentiation by Myostatin Treatment in 3T3-L1 Cultures”,Biochem. Biophys. Res. Comm., 281:902-906 (2001).
Kingsley, D.M., “The TGF-β Superfamily: New Members, New Receptors, and New Genetic Tests of Function in Different Organisms”,Genes&Devel. 8:133-146 (1994).
Lee et al., “Regulation of Myostatin Activity and Muscle Growth”,PNAS98:9306-9311 (2001).
Massagué, J., “The Transforming Growth Factor-β Family”, Ann. Rev. Cell Biol. 6:597-641 (1990).
McPherron et al., “Suppression of Body Fat Accumulation in Myostatin-Deficient Mice”,J. Clin. Invest. 109:595-601 (2002).
McPherron et al., “Regulation of Skeletal Muscle Mass in Mice by a New TGF-β Superfamily Member”,Nature387:83-90 (1997).
McPherron et al., “Double Muscling in Cattle Due to Mutations in the Myostatin Gene”,PNAS94:12457-12461 (1997).
Miyazono et al., “Latent High Molecular Weight Complex of Transforming Growth Factor β1”,J. Biol. Chem. 263:6407-6415 (1988).
Nakashima et al., “Expression of Growth/Differentiation Factor 11, A New Member of the BMP/TGF β Superfamily During Mouse Embryogenesis”,Mech. Dev. 80:185-189 (1999).
Swatland et al., “Fetal Development of the Double Muscled Condition in Cattle”,J. Animal Sci. 38:752-757 (1974).
Thies et al., “GDF-8 Propeptide Binds to GDF-8 and Antagonizes Biological Activity by Inhibiting GDF-8 Receptor Binding”,Growth Factors18:251-259 (2001).
Wagner et al., “Loss of Myostatin Attenuates Severity of Muscular Dystrophy inmdxMice”,Ann. Neurol. 52:832-836 (2002).
Wakefield et al., “Latent Transforming Growth Factor- β From Human Platelets”,J. Biol. Chem. 263:7646-7654 (1988).
Whittemore et al., “Inhibition of Myostatin in Adult Mice Increases Skeletal Muscle Mass and Strength”,Biochem. Biophys. Res. Comm. 300:965-971 (2003).
Zimmers et al., “Induction of Cachexia in Mice by Systematically Administered Myostatin”,Science296:1486-1488 (2002).
International Search Report, PCT/IB 03/04745, mailed Jun. 1, 2004.
Hill, J. et al., “The Mytostatin Propeptide and the Folliistatin-related Gene Are Inhibitory Binding Proteins of Myostatin in Normal Serum,”J. Biol. Chem. 277:40735-40741 (2002).
Alliel et al., “Testican, a Multidomain Testicular Proteoglycan Resembling Modulators of Cell Social Behaviour,”Eur. J. Biochem. 214:347-350 (1993).
Amthor et al., “The Expression and Regulation of Follistatin and a Follistatin-like Gene During Avian Somite Compartmentalization and Myogenesis,”Dev. Biol. 178:343-362 (1996).
Attisano et al., “Activation of Signalling by the Activin Receptor Complex,”Mol. Cell. Biol. 16:1066-1073 (1996).
Bakker et al., Duchenne and Becker Muscular Dystrophies. InDiagnostic Criteria for Neuromuscular Disorders, 2nd ed., Emery, ed., Royal Society of Medicine Press, 1998; pp. 1-4.
Bartholin et al., “FLRG, an Activin-Binding Protein, is a New Target of TGFβ Transcription Activation Through Smad Proteins,”Oncogene20:5409-5419 (2001).
Bulfield et al., “X Chromosome-Linked Muscular Dystrophy (mdx) in the Mouse,”Proc. Natl. Acad. Sci. U.S.A. 81:1189-1192 (1984).
D
Bridges Kristie Grove
Davies Monique V.
Field Anne
Russell Caroline
Song Kening
Cambridge Antibody Technology Limited
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
Kemmerer Elizabeth C.
Wyeth
LandOfFree
Neutralizing antibodies against GDF-8 and uses therefor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Neutralizing antibodies against GDF-8 and uses therefor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neutralizing antibodies against GDF-8 and uses therefor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3842705